Annovis’ cash and cash equivalents totaled $15.3 million as of September 30, 2025, compared to $10.6 million as of December 31, 2024. This includes gross proceeds from its recent $6.0 million and $3.4 million registered direct offerings in October, enabling the Company to fund its operations to the third quarter of 2026. Annovis had 20.2 million shares of common stock outstanding as of September 30, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Optimistic Buy Rating for Annovis Bio Amid Promising Alzheimer’s Clinical Developments
- Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD
- Annovis Bio Announces Securities Purchase Agreement
- Annovis Bio prices 1.67M shares at $2.05 in registered direct offering
- Annovis Bio Announces $6M Stock Offering